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OBJECTIVE: To analyze the impact of model for end-stage liver disease (MELD) allocation policy on survival
outcomes after liver transplantation (LT).
INTRODUCTION: Considering that an ideal system of grafts allocation should also ensure improved survival after
transplantation, changes in allocation policies need to be evaluated in different contexts as an evolutionary process.
METHODS: A retrospective cohort study was carried out among patients who underwent LT at the University of
Pernambuco. Two groups of patients transplanted before and after the MELD allocation policy implementation
were identified and compared using early postoperative mortality and post-LT survival as end-points.
RESULTS: Overall, early postoperative mortality did not significantly differ between cohorts (16.43% vs. 8.14%;
p=0.112). Although at 6 and 36-months the difference between pre- vs. post-MELD survival was only marginally
significant (p=0.066 and p=0.063; respectively), better short, medium and long-term post-LT survival were
observed in the post-MELD period. Subgroups analysis showed special benefits to patients categorized as non-
hepatocellular carcinoma (non-HCC) and moderate risk, as determined by MELD score (15-20).
DISCUSSION: This study ensured a more robust estimate of how the MELD policy affected post-LT survival outcomes
in Brazil and was the first to show significantly better survival after this new policy was implemented. Additionally,
we explored some potential reasons for our divergent survival outcomes.
CONCLUSION: Better survival outcomes were observed in this study after implementation of the MELD criterion,
particularly amongst patients categorized as non-HCC and moderate risk by MELD scoring. Governmental
involvement in organ transplantation was possibly the main reason for improved survival.
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INTRODUCTION
Initially described by Malinchoc et al.
1 as a mathematical
model for predicting survival in the first three months
postoperatively for patients who underwent percutaneous
placement of transjugular intrahepatic porto-systemic shunt
(TIPS), the model for end-stage liver disease (MELD)
score was quickly validated as a predictor of mortality
for a wide variety of liver diseases,
2-4 including cirrhotic
patients awaiting liver transplantation (LT).
5-8
Afterwards, to reduce mortality amongst patients on the
waiting list
9,10 and to eliminate possible confounding
factors, the MELD criterion was incorporated as a more
transparent and objective system, based on easily measur-
able laboratory tests.
11-13 The implementation of this model
was based on the recognition that time on the list was an
inadequate criterion for prioritizing candidates for LT, since
it had little relationship to mortality in these patients.
12,13
Therefore, considering that an ideal system of graft
allocation should ensure the best use of available livers for
mortality reduction amongst patients on waiting lists and
improvement of survival after transplantation,
5 changes in
allocation policies need to be evaluated in different contexts
over time. In addition, as the MELD criterion has only
recently been implemented in Brazil (2006), only medium-
term post-transplant survivals could be compared with
those observed in the period before its introduction.
14
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57This current study describes a Brazilian single-center
experience and provides a comparison between pre- vs.
post-MELD cohorts to analyze the impact of MELD
allocation policy on survival outcomes after LT at the
Department of Surgery and Liver Transplantation of the
Oswaldo Cruz University Hospital (HUOC), University of
Pernambuco.
MATERIALS AND METHODS
Study Population and Data Collection
A retrospective cohort study was carried out on patients
transplanted by the Department of General Surgery and
Liver Transplantation of the Oswaldo Cruz University
Hospital, University of Pernambuco, from July 15, 2003 to
July 14, 2009. Using our own database, two groups of
patients transplanted before and after MELD allocation
policy implementation were identified: pre-MELD group—
those undergoing LT from July 15, 2003 to July 14, 2006
(n=113); and Post-MELD group—those undergoing LT
between July 15, 2006 and July 14, 2009 (n=185).
The same surgical team performed all procedures using
standard technique without veno-venous bypass and with
conventional or piggyback hepato-venous reconstruction.
After LT, tacrolimus, mycophenolate (sodium or mofetil)
and prednisone were used as immunosuppressive treat-
ment, with no changes in the protocols applied from 2003 to
2009. All patients were followed for at least one year in
order to determine the primary endpoint (death).
We limited our study to adults and adolescent patients
(.16 years) who received deceased donor orthotopic LT.
For patients who had undergone re-transplantations, data
were collected from the first procedure only and recipients
of split-liver or sequential (domino) transplants were not
eligible for this study. We also excluded patients trans-
planted as a result of fulminant hepatic failure, as well as
patients with incomplete data in their medical records.
Variables and Outcomes
Descriptive statistics include donor and recipient ages,
cold (CIT) and warm ischemia times (WIT), amounts of red
blood cells (RBC) and platelets transfused at the surgery,
MELD score and monthly transplant rates as continuous
variables. As categorical variables, Child-Pugh classing,
ABO blood grouping, pre-transplant diagnosis, reci-
pient gender and hepato-venous reconstruction type were
studied.
Two different survival outcomes were compared between
pre- vs. post-MELD groups: early postoperative mortality
and patient post-LT survival. Early postoperative mortality
rates were defined as the proportion of deaths in the first
30 days after LT. Patient survival, as a function of time after
transplantation until the date of death or end of the study,
was explored as short- (3 and 6 months), medium- (1 year)
and long-term (3 years) outcomes. Data on deaths not
related to liver disease or transplant procedure, and data on
those patients alive at the end of the study, were ‘‘censored’’
for cumulative survival estimation.
MELD score was calculated using laboratory results
collected immediately prior to the LT
15 with no adjustments
for malignancy or other ‘‘special’’ conditions used to
prioritize these patients on the waiting list.
16 Serum markers
were used to confirm viral hepatitis diagnosis. The pre-
operative diagnosis of hepatocellular carcinoma (HCC) was
based on the Barcelona-2000 conference diagnostic criteria
17
and confirmed by explant pathology. The Milan criteria
were applied as a basis for selecting patients with HCC for
LT.
Sample Characteristics
Our group performed 298 LTs in 288 patients during the
period described earlier. Eighty patients were not eligible or
excluded from this study, and 208 patients were included in
the analysis (pre-MELD=73 vs. post-MELD=135). Patient
characteristics, as well as transplant Center and donor
variables, are summarized in Table 1. Seventy-seven percent
of HCC patients had other associated diagnoses, among
which viral C hepatitis was the most common disease
(52.45%).
Follow-up data were available for the entire study group
(n = 208). Over the 82.6 month follow-up period, 68 liver
allograft recipients died (36.7%) and 7 (3.4%) underwent re-
transplantations. The main causes of death were infection,
malignancy recurrence and liver failure/transplant rejec-
tion.
Analytic Approach
The statistical analyses were performed using the
STATISTICA Data Analysis Software System, Version 8.0
(Statsoft, Inc., Tulsa, OK, USA), and all analyses considered
a two-tailed p-value of 0.05 as statistically significant.
Normal distribution was not proven for the clinical
variables available (Kolmogorov–Smirnov test, p,0.05);
then, nonparametric tests were applied to all data analysis.
For descriptive analyses, we summarized the continuous
variables using medians (interquartile range) and catego-
rical variables as proportions.
Comparisons between pre- vs. post-MELD groups were
conducted using the Mann-Whitney U-test for continuous
variables and chi-square tests for categorical variables,
including Yates’s correction or Fischer’s exact test as
appropriate. Rates of postoperative early mortality were
compared using chi-square tests and survival probabilities
were constructed using Kaplan–Meier survival estimates
and compared using the log-rank test.
Furthermore, as a result of the introduction of the MELD
allocation policy to prioritize the sickest patients and the
well-known increase in the rates of LT for HCC in the post-
MELD era,
10-12,14,18-24 we also stratified the patients accord-
ing to MELD score and diagnosis, in order to control for
these variables. Patients were stratified according to MELD
score to low-risk (,15), medium-risk (15–20) or high-risk
(.20) categories.
9 According to diagnosis, these patients
were stratified as HCC or non-HCC.
Additionally, we explored some potential reasons for
divergent survival outcomes after implementation of the
MELD-based policy, using a cross-sectional strategy. For
this analysis, we applied c-statistic, univariate and multi-
variate analyses to check our hypothesis, as described
below.
The prognostic value of MELD score in predicting post-
LT survival was assessed using receiver operating char-
acteristic (ROC) curve analysis. The c-statistic, equivalent to
the area under the ROC curve (AUC), was adopted to
establish the overall diagnostic accuracy of the MELD score.
Usually, AUC between 0.8 and 0.9 indicates excellent
diagnostic accuracy; a score with an AUC.0.7 should be
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58considered clinically useful and AUC # 0.5 is considered to
be indicative of a lack of discriminating power.
9,25,26
The association of each demographic variable with long-
term post-LT survival was also tested using the log-rank test
ina univariateanalysis.Forthisapproach,wecategorizedthe
continuous variables using current cut-off points.
9,21,27-31
Then, factors whose association with survival showed a p-
value ,0.20 were used in a multivariate Cox’s proportional-
hazards model to identify the independent predictors. We
also adjusted this multivariate analysis for transplantation
era (first vs. second transplantation era) and allocation
criterion (pre- vs. post-MELD).
Finally, we explored survival in consecutive transplanta-
tions eras using the Kaplan-Meier method and the log-rank
test. As follow-up of patients who have recently undergone
transplantation is often small, we limited this study to a one-
year analysis of four successive transplantation periods
(quartiles) and to a two-year analysis of two successive
transplantation eras. The significant variables highlighted in
the previous multivariate analysis were also compared
among the transplantation quartiles using the Kruskal-
Wallis test.
Ethical Comments
This study was registered in the Brazilian National
System of Human Research – SISNEP (CAAE - 0003.0.106.
000/10) and approved by the HUOC Ethics Research
Committee (protocol number 12/2010). All procedures
complied with the standards of the Declaration of Helsinki
and current ethical guidelines.
RESULTS
As summarized in Table 1, a statistically significant
increase in monthly transplant rates (p,0.001), proportion
of HCC patients (p,0.001) and use of the piggyback hepato-
venous technique (p=0.039) were found in the post-MELD
cohort. A significant reduction of WIT was also observed
after implementation of the MELD criterion (p,0.001) and
the overall median MELD score remained unchanged after
its introduction (p,0.073). In the HCC sub-group, this score
was lower than among non-HCC patients (p,0.001) and
displayed no change during the post-MELD era (p=0.501).
On the other hand, the median MELD score rose 3.5 points
in this period in the non-HCC sub-group (p,0.001).
Table 1 - Descriptive statistics of measured variables.
Study Cohorts
Median (interquartile range) or n (%)
Variables
Overall
Median (interquartile range) or n (%) Pre-MELD Post-MELD p-value
1
Recipient variables
Recipient age (years) 54 (44.5-60.5) 52 (45-59) 55 (44-61) 0.207
MELD Score 15 (12-19) 15 (12-17) 15 (12-20) 0.073
HCC 13 (10-15) 13 (12-16) 13 (10-15) 0.501
Non-HCC 17 (13-20) 15 (11-17) 18.5 (14-21.5) ,0.001
Gender 0.858
Male 137 (65.86) 47 (64.38) 90 (66.66)
Female 71 (34.13) 26 (35.61) 45 (33.33)
ABO blood group 0.953
A 84 (40.38) 32 (43.83) 52 (38.51)
B 24 (11.53) 7 (9.58) 17 (12.59)
AB 11 (5.28) 2 (2.73) 9 (6.66)
O 89 (42.78) 32 (43.83) 57 (42.22)
Child-Pugh class 0.926
A 53 (25.48) 17 (23.28) 36 (26.66)
B 94 (45.19) 37 (50.68) 57 (42.22)
C 61 (29.32) 19 (26.02) 42 (31.11)
Diagnosis
2
Chronic viral hepatitis 86 (41.34) 32 (43.83) 54 (40) 0.697
HCC 61 (29.32) 10 (13.69) 51 (37.77) ,0.001
Alcoholic cirrhosis 53 (25.48) 21 (28.76) 32 (23.70) 0.526
Cryptogenic cirrhosis 25 (12.01) 10 (1.36) 15 (11.11) 0.745
Autoimmune chronic Hepatitis 13 (6.25) 6 (2.88) 7 (5.18) 0.385
Cholestatic liver Disease
3 11 (5.28) 3 (1.44) 8 (5.92) 0.750
Miscellaneous 51 (24.51) 16 (21.91) 35 (25.92) 0.636
Donor and center variables
Monthly transplant rate 6 (4-8) 4 (3-6) 6 (5-8) ,0.001
Donor age (years) 40.5 (25.5-51) 42 (26-51) 39 (25-51) 0.974
Cold ischemia time (hours) 6.8 (5.4-8.7) 7 (5.6-8.6) 6.6 (5.4-8.7) 0.533
Warm ischemia time (minutes) 47.5 (40-55) 55 (45-60) 45 (37-51) ,0.001
Red blood cells Transfusion (units) 3 (1-5) 3 (2-5) 3 (1-5) 0.626
Platelets transfusion (units) 0 (0-9) 0 (0-7) 0 (0-10) 0.666
Hepato-venous reconstruction 0.039
Conventional 127 (61.06) 52 (71.23) 75 (55.56)
Piggyback 81 (38.94) 21 (28.77) 60 (44.44)
1Comparisons between Pre- vs. Post-MELD cohorts using the Mann-Whitney U-test for continuous variables or chi-square tests for categorical variables
2Categories were not mutually exclusive, so multiple diagnoses were possible.
3Primary biliary cirrhosis and primary sclerosing cholangitis.
MELD = model for end-stage liver disease; HCC = hepatocellular carcinoma; non-HCC = non-hepatocellular carcinoma.
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59The overall early postoperative mortality was 11.05% and
showed no statistical difference between the cohorts (16.43%
vs. 8.14%; p=0.112). Similarly, the inter-group study
showed no statistical difference between patients categor-
ized according to diagnosis (p=0.545) or MELD score (p=
0.994). However, the subgroups analysis showed a statisti-
cally significant reduction in mortality rate after introduc-
tion of the MELD criterion in the patients categorized as
moderate-risk by MELD score (p=0.039). We also found a
borderline statistical significance in the non-HCC subgroup
(p=0.054) (Table 2).
Patients 3, 6, 12 and 36-months overall cumulative survi-
vals were 85.1, 79.3, 74.5 and 67.5%, respectively. Although
the difference between pre- vs. post-MELD survival rates
was sometimes only marginally significant, better rates of
post-LT survival were observed in the post-MELD era
(Figure 1). The inter-group analysis showed no statistical
difference in survival amongst patients stratified according
to diagnosis or MELD score (Figure 2), but statistically
higher cumulative survivals were found in the sub-group
analysis of non-HCC and moderate-risk MELD score
categories in the post-MELD period (Table 3).
According to c-statistic, the accuracy of preoperative
MELD score in predicting post-LT survival was 0.526, 0.524,
0.5 and 0.519, at 3, 6, 12 and 36-months, respectively. After
univariate and multivariate analyses, only transfusion of
RBC ($5 units) was an independent predictor of poorer 3-
year post-LT survival, although differences in CIT ($12
hours) were also of borderline statistical significance. These
findings remained unchanged after adjustment for trans-
plantation era and allocation criterion (Table 4).
The patients transplanted with piggyback hepato-venous
anastomosis presented significantly better post-LT survival
in the univariate analysis (60.44% vs. 79.15%. p=0.006);
however, this statistical significance was lost in the multi-
variate analysis. This technique was also associated with
lower RBC transfusion and WIT (p=0.032 and p,0.001,
respectively).
We found increased survival from first to fourth
transplantation quartiles in a one-year survival analysis
(61.5% vs. 73.1% vs. 75% vs. 88.5%, respectively. p=0.027),
as well as in the first vs. second transplantation era, as
determined using two-year survival as an end-point (62.5%
vs. 80.4%, respectively, p=0.005). There were no significant
differences in RBC transfusion or CIT into the transplanta-
tion quartiles (p=0.177 and p=0.608, respectively).
DISCUSSION
Since July 2006, the MELD criterion has been adopted to
guide organ allocation at the national level for LT in Brazil.
16
The implementation of this new allocation policy was
followed by significant increases in the monthly rates of
LT and, therefore, the total number of procedures per-
formed by our department. This also occurred at other
Table 2 - Early postoperative mortality rates.
Study Cohorts
n( % )
Mortality Rates n (%) Pre-MELD Post-MELD p-value
1
Overall 23 (11.05) 12 (16.43) 11 (8.14) 0.112
Diagnostic Categories
HCC 5 (8.19) 0 (0) 5 (9.80) 0.579





MELD ,15 9 (9.67) 5 (14.28) 4 (6.89) 0.289
MELD 15-20 10 (12.82) 7 (23.33) 3 (6.25) 0.039
MELD .20 4 (10.81) 0 (0) 4 (13.79) 0.557
p-value
2 0.994
1Comparison between Pre vs. Post-MELD cohorts using chi-square tests.
2Inter-group comparisons were performed using the chi-square test.
MELD = model for end-stage liver disease; HCC = hepatocellular
carcinoma; non-HCC = non-hepatocellular carcinoma.
Figure 1 - Overall patient survival (Kaplan-Meier) before and after the model for end-stage liver disease (MELD) criterion
implementation. There was improved patient survival at three years (with a borderline statistical significance) among the post-MELD
cohort as compared to the pre-MELD cohort (60.27% vs. 72.62%, p=0.063, by the log-rank test).
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60Centers,
10,11,21,32 likely reflecting recent increase in Public
Health System involvement in the transplantation of organs
and tissues.
10,33
As a result of the prioritization of patients in ‘‘special
situations’’ dictated by the new liver grafts allocation
policy,
16 there was a significant increase in the number of
patients transplanted as a result of HCC in our department,
as well as around the world.
11,12,14,18-24,32,34
Contrary to the findings of other authors, we did not find
an overall increased severity of liver disease in the patients
transplanted after the introduction of the MELD-based
policy.
11,21,35 However, this may be as a result of the higher
proportion of HCC patients transplanted in the post-MELD
period. Such patients typically have better hepatic func-
tional reserves
10,21,36 and exhibit no change in the severity of
their liver disease after adoption of the MELD criterion.
Moreover, "dilution" of the MELD scores by the increase in
monthly transplant rates
21 and the shorter time spent
awaiting LT in our State during the post-MELD period
10
may have reduced MELD scores.
Although the difference between pre- vs. post-MELD
survival has sometimes been only marginally significant,
analysis of our liver transplant database reveals that the most
important post-transplantation outcome—namely patient
Figure 2 - Kaplan-Meier analysis of patients stratified according to diagnosis (A) and model for end-stage liver disease (MELD) score risk
category (B). Inter-group analysis showed no difference in patient survival at three years (p=0.350 and p=0.887, respectively, by the
log-rank test).
Table 3 - Stratified cumulative proportion surviving after liver transplantation.
Cumulative Proportion Surviving (%)
1
Groups and Categories n (%) 3 months 6 months 12 months 36 months
Overall
Pre-MELD 73 (35.10) 77.62 72.57 65.75 60.27
Post-MELD 135 (64.90) 88.76 82.96 79.25 72.62
p-value
2 0.036 0.066 0.028 0.063
HCC
Pre-MELD 10 (16.39) 100.00 100.00 90.00 80.00
Post-MELD 51 (83.60) 86.00 76.47 70.58 57.27
p-value
2 0.217 0.090 0.174 0.141
Non-HCC
Pre-MELD 63 (42.85) 73.98 68.21 61.90 57.14
Post-MELD 84 (57.14) 90.41 86.90 84.52 83.28
p-value
2 0.009 0.005 0.001 0.001
MELD ,15
Pre-MELD 35 (37.63) 79.41 74.28 68.57 62.85
Post-MELD 58 (62.36) 87.71 82.75 79.31 70.35
p-value
2 0.292 0.313 0.241 0.402
MELD 15-20
Pre-MELD 30 (38.46) 72.41 66.66 63.33 60.00
Post-MELD 48 (61.53) 91.66 85.41 85.41 78.32
p-value
2 0.029 0.042 0.021 0.056
MELD .20
Pre-MELD 8 (21.62) 87.50 87.50 62.50 50.00
Post-MELD 29 (78.38) 85.96 79.31 68.96 68.96
p-value
2 0.874 0.588 0.785 0.604
1Kaplan-Meier method.
2Comparison between Pre- vs. Post-MELD cohorts using the log-rank test.
MELD = model for end-stage liver disease; HCC = hepatocellular carcinoma; non-HCC = non-hepatocellular carcinoma.
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61survival—has improved since the implementation of the
MELD-based liver allocation system. In order to explore these
divergent outcomes,
11,14,21,37 we conducted some additional
exploratory analyses to elucidate our findings further.
First, as factors related to cancer alone are not enough to
predict the prognosis of patients with HCC
4 and because
such patients exhibit better liver function at the time of
LT,
5,10,21,36 we expected better survival for these patients
and supposed it as the main reason for our improved post-
LT survival during the post-MELD period.
36 However, our
data have shown that HCC patient survival did not improve
after introduction of the MELD criterion. Furthermore, there
was no significant difference in early postoperative mortal-
ity or post-LT survival between HCC vs. non-HCC patients.
Therefore, the best results observed during the post-MELD
period did not result from the greater proportion of HCC
patients transplanted in this period. We also noticed a trend
of worsening survival after one year of LT in this patient
subgroup, which probably resulted from the influence of
tumor-related factors.
38
A second possible explanation is that transplant recipients
are simply not sicker in the post- vs. pre-MELD periods.
Nonetheless, our data failed to confirm this hypothesis.
Despite the lack of any change in liver disease severity in the
HCC subgroup, the non-HCC patients exhibited a 3.5-point
increase in median MELD score during the post-MELD era.
This approach also demonstrated an apparent disconnect
between liver disease severity and survival outcomes in the
non-HCC subgroup, which presented significantly higher
cumulative survival after adoption of the MELD criterion.
Similarly, a lower early postoperative mortality rate, with
borderline statistical significance, could also be observed
amongst these patients in the post-MELD era.
Although it is plausible to hypothesize that patients
transplanted with higher MELD scores had worse survi-
val,
10,21,22 our data show there was no significant difference
among patient groups with different MELD scores. This
finding suggests MELD score is not a good predictor of
post-LT survival. We also used the c-statistic to confirm that
preoperative MELD score had poor discriminatory power in
predicting post-LT survival among patients treated in our
department.
Similarly, in a systematic review about the performance of
MELD in the setting of LT, Colongita et al. concluded that
MELD score is not a good predictor for short-term mortality
after LT and that further studies were needed to assess long-
term performance.
5 In addition, it has been demonstrated that
this score does not have the same prognostic accuracy among
patients with milder degrees of hepatic cirrhosis and that the
effect of hepatic dysfunction may not be evident at MELD
score values lower than 30.
5,39 This suggests only high MELD
values affect post-LT survival.
21 Therefore, although statisti-
cally significant, the 3.5-point increases that represent shifts to
milder degrees of hepatic dysfunction (i.e. MELD 15-20), may
not translate into a clinically relevant difference in survival.
On the other hand, worse survival in recipients with
higher MELD scores has been cited by some authors
9,14,35
and higher MELD scores have also been linked to greater
postoperative morbidity.
40,41 However, even in patients
with more severe disease, there is a clear survival benefit
from LT, because of their corresponding lower survival
rates on the waiting list without LT
42-44 As demonstrated by
Merion et al.,
42 the benefit of LT would become evident only
in patients with MELD scores higher than 18 and the
magnitude of this benefit increased with increasing MELD
score. Similar results were also described by Gleisner et al.,
who suggested a MELD score of 15 as a transition point in
terms of overall survival benefit.
44
Although the MELD criterion was established to prior-
itize the sickest patients, a large proportion of transplanted
recipients do not have severe liver disease, as evaluated by
MELD score.
5 Accordingly, in our department the median
MELD score did not change with the introduction of the
MELD criterion and remained low (15 points) after
implementation (HCC=13 and non-HCC=18.5). Similarly,
only 3.4% of patients had MELD scores greater than 30 (data
not shown). These low proportions of patients with high
MELD scores have also been found in other studies
5,22,35,42





2 Unadjusted Allocation Criterion Transplantation Era
4
Diagnostic categories
5 0.350 – – –
ABO blood group 0.120 0.279 0.361 0.320
Receptor gender 0.635 – – –
Recipient age (,55 vs. $55) 0.973 – – –
MELD (,15 vs.15-20 vs. .20) 0.887 – – –
Child-Pugh class 0.400 – – –
Donor age (,50 vs. $50) 0.660 – – –
Cold ischemia (,12 vs. $12) 0.018 0.062 0.050 0.060
Warm ischemia (,45 vs. $45) 0.048 0.419 0.694 0.825
Red blood cells (,5v s .$5) ,0.001 0.002 0.002 0.003
Platelets (yes vs. no) 0.027 0.547 0.573 0.666
Transplant rate (,5 vs. $5) 0.424 – – –
Hepato-venous Reconstruction
6 0.006 0.119 0.135 0.128
1Continuous variables categorized as in parentheses.
2Univariate analysis using the log-rank test.
3Multivariate analysis using the Cox-proportional hazards model. This analysis was also adjusted to group the patients according to allocation criterion
(pre-MELD vs. post-MELD) and transplantation era (first era vs. second era).
4First era: 7/15/2003 – 8/28/2007; second era: 8/29/2007 – 7/14/2009.
5HCC vs. non-HCC patients.
6Piggyback vs. conventional hepato-venous anastomosis.
MELD = model for end-stage liver disease; HCC = hepatocellular carcinoma; non-HCC = non-hepatocellular carcinoma.
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62and probably contributed to reducing the accuracy of this
score in predicting post-LT survival in our department.
Other potential explanations were that better survival
outcomes in the post-MELD period may have resulted from
our increased case volume and/or from a higher proportion
of patients transplanted with the piggyback technique. In order
to explore this hypothesis, we additionally performed a
secondarystatistical approachto explore long-termpredictors
of survival using univariate and multivariate analysis.
According to this approach, transfusion of RBC alone ($5
units) was an independent predictor of poorer three-year
post-LT survival; however, CIT $12 hours also exhibited
borderline statistical significanceasanindependentpredictor.
In a previous study at our department, the piggyback tech-
nique was associated with reduced length of hospital stay,
surgical time and WIT, as well as a better 30-day post-LT
survival.
45 Accordingly, in our long-term univariate analysis,
we found better post-LT survival amongst patients trans-
planted with the piggyback hepato-venous anastomosis. How-
ever,ourmultivariateanalysisrevealedthisoutcomeprobably
resulted from the reduced RBC transfusion that accompanies
this technique. The higher proportion of patients transplanted
with this technique in the post-MELD era also served to
explain our lower WIT observed during this last period.
As our department changed from a medium case volume
center (20-50 LT /year) in the pre-MELD period of the study
to a high case volume center (.50LT/year) in the post-MELD
era,
21 as well as the better outcomes observed at LT Centers
performing more than 20 procedures per year,
46 we hypothe-
sized that increased LT volume was a plausible reason for
better survival after implementation of the MELD allocation
plan. Nevertheless, our monthly transplantation rates did not
correlate with patient survival in this study. Furthermore,
because our study started after more than 40 LTs had been
performed by our department, center- and team-related
factors (i.e. case volume and transplantation experience)
appear to not have significantly influenced patient survival
at our department. Similarly, Northup et al. explored the
impact of transplant center case volume on survival of 9909
adult liver transplants performed in the USA since the
beginning of the MELD allocation system.
47 After adjusting
for disease severity and multiple donor and recipient factors,
transplantcentervolumewasnolongerasignificantpredictor
of post-LT survival, according to these authors.
As alternative reasons for our better survival outcomes in
the post-MELD period, we finally hypothesized that
involvement of the Public Health System in the transplanta-
tion of organs and tissues played a role.
10,33 To support this
hypothesis, we explored our analysis of patient survival to
include successive transplantation periods. Using this
approach, we found increased survival from first to fourth
transplantation quartiles in a one-year survival analysis as
well as in the first vs. second transplantation era, using two-
year survival as the end-point. Moreover, we also confirmed
there were no differences in RBC transfusion or CIT among
successive transplantation quartiles.
Notably, in the post-MELD period, governmental efforts
to encourage organ transplantation improved the logistics of
the donation-transplant process, allowing for an increase in
the number of potential donors in brain-death notifications
and in the amount of donations and transplants in the State
of Pernambuco.
10,33 Furthermore, governmental involve-
ment also included some educational, structural and
financial improvements that gradually impacted on regional
medical assistance
33 and may have contributed to better
survival during the most recent periods of our LT activity.
Our analysis has three main strengths: firstly, whereas a
previous report
14 with similar methods measured medium-
term post-LT survival (1-year), we provided a 3-year
survival analysis. This approach ensured a more robust
estimate of how the MELD policy affected post-LT survival
outcomes in Brazil; secondly, we were the first center to
show significantly better survival after the implementation
of a MELD-based policy.
11,14,21,37 Similarly, although
MELD-based policy has not significantly reduced waiting
list mortality throughout the country,
48,49 our State pre-
sented lower waiting list mortality after adoption of this
new system;
10 and lastly, we explored potential reasons for
our divergent survival outcomes after LT.
However, there were also limitations with our study.
Firstly, few patients in the HCC and MELD .20 subgroups
underwent transplantation during the pre-MELD era at our
department, which limited their subgroup analyses to
comparisons between the pre- vs. post-MELD periods.
Secondly, a small proportion of our patients had high
‘‘calculated’’ MELD scores [i.e. only 3.4% had MELD scores
.30 and just 8.2% had MELD scores $25 (data not shown)].
Notably, a low proportion of patients with high MELD
scores probably minimized the accuracy of this score in
predicting post-LT survival, as well as the impact of MELD-
based policy on our post-LT survival outcomes. Lastly,
analysis of additional donor-related variables could provide
additional information, because a large proportion of
extended-criteria donors were used at our department.
28,50
CONCLUSION
In conclusion, better survival outcomes were observed in
our department after implementation of the MELD alloca-
tion policy, particularly amongst patients categorized as
non-HCC and moderate-risk, as determined by MELD score
(15-20 points). Gradual involvement of the Public Health
System in organ transplantation was possibly the main
reason for the improvement in survival outcomes.
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